Arthur M. Cohen & Associates LLC Sells 2,377 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Arthur M. Cohen & Associates LLC lowered its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLIFree Report) by 18.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 10,564 shares of the company’s stock after selling 2,377 shares during the period. Arthur M. Cohen & Associates LLC’s holdings in Denali Therapeutics were worth $227,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. JPMorgan Chase & Co. increased its position in shares of Denali Therapeutics by 17.1% during the first quarter. JPMorgan Chase & Co. now owns 97,372 shares of the company’s stock valued at $3,133,000 after buying an additional 14,227 shares during the period. MetLife Investment Management LLC lifted its position in Denali Therapeutics by 55.6% during the first quarter. MetLife Investment Management LLC now owns 50,392 shares of the company’s stock valued at $1,621,000 after buying an additional 18,003 shares during the period. Rhumbline Advisers grew its position in shares of Denali Therapeutics by 0.5% in the 1st quarter. Rhumbline Advisers now owns 97,145 shares of the company’s stock worth $3,125,000 after buying an additional 496 shares during the period. BlackRock Inc. increased its stake in shares of Denali Therapeutics by 0.9% in the 1st quarter. BlackRock Inc. now owns 8,185,740 shares of the company’s stock worth $263,336,000 after acquiring an additional 74,918 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Denali Therapeutics by 13.7% during the first quarter. Dimensional Fund Advisors LP now owns 878,224 shares of the company’s stock worth $28,253,000 after acquiring an additional 106,027 shares in the last quarter. 78.04% of the stock is owned by institutional investors.

Insider Activity at Denali Therapeutics

In other news, Director Vicki L. Sato sold 1,666 shares of Denali Therapeutics stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $18.37, for a total transaction of $30,604.42. Following the completion of the sale, the director now directly owns 121,375 shares in the company, valued at approximately $2,229,658.75. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CEO Ryan J. Watts sold 17,483 shares of the firm’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $19.43, for a total value of $339,694.69. Following the completion of the sale, the chief executive officer now directly owns 2,276,181 shares in the company, valued at $44,226,196.83. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $18.37, for a total transaction of $30,604.42. Following the completion of the sale, the director now owns 121,375 shares of the company’s stock, valued at approximately $2,229,658.75. The disclosure for this sale can be found here. Insiders sold 61,604 shares of company stock worth $1,161,976 in the last quarter. 7.90% of the stock is owned by company insiders.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI opened at $20.13 on Monday. Denali Therapeutics Inc. has a 1 year low of $15.45 and a 1 year high of $33.31. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of -18.64 and a beta of 1.34. The stock’s 50-day simple moving average is $18.34 and its 200-day simple moving average is $19.80.

Denali Therapeutics (NASDAQ:DNLIGet Free Report) last posted its earnings results on Tuesday, February 27th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.05). Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 13.50%. During the same period in the prior year, the business earned ($0.75) EPS. As a group, research analysts predict that Denali Therapeutics Inc. will post -2.66 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on DNLI. HC Wainwright dropped their target price on Denali Therapeutics from $105.00 to $95.00 and set a “buy” rating on the stock in a report on Wednesday, February 28th. Wedbush reiterated an “outperform” rating and issued a $31.00 price objective on shares of Denali Therapeutics in a research note on Wednesday, February 28th. Citigroup assumed coverage on Denali Therapeutics in a research note on Wednesday, December 13th. They issued a “buy” rating and a $32.00 price objective on the stock. The Goldman Sachs Group decreased their target price on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, February 29th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating and set a $28.00 price target on shares of Denali Therapeutics in a research note on Monday, November 20th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Buy” and an average price target of $44.67.

Read Our Latest Research Report on DNLI

About Denali Therapeutics

(Free Report)

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Further Reading

Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLIFree Report).

Institutional Ownership by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.